The future of hypertension therapy: Sense, antisense, or nonsense?

Hypertension

Volumn 37, Issue 2 II, 2001, Pages 357-364

  Pachori, Alok S ^a   Huentelman, Matthew J ^a   Francis, Sharon C ^a   Gelband, Craig H ^a   Katovich, Michael J ^a   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense elements; Genes; Genetic; Hypertension; Rats; Renin angiotensin system; Spontaneously hypertensive

Indexed keywords

COMPLEMENTARY RNA;

CONFERENCE PAPER; DNA VECTOR; GENE TARGETING; GENE THERAPY; HYPERTENSION; INCIDENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0035090127     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.37.2.357     Document Type: Conference Paper

References (52)

1. Hypertension
2. Angiotensin II receptor antagonists: A new approach to blockade of the rennin-angiotensin system
3. Blood pressure, systolic and diastolic and cardiovascular risks
4. Molecular genetics of human hypertension
5. Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension
6. An overview of essential hypertension in Americans as a multifactorial phenomenon: Interaction of biologic and environmental factors
7. Hypertension genes and environment
8. Is antisense gene therapy a step in the right direction in the control of hypertension?
9. Targeting of the rennin-angiotensin system by antisense gene therapy: A possible strategy for the long-term control of hypertension
10. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in salt sensitive rats
11. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery
12. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats
13. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats
14. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukemia cells
15. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides
16. 1; receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin
17. 1R mRNA antisense
18. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy
19. Is antisense gene therapy a step in the right direction in the control of hypertension?
20. Strategies for targeted gene therapy
21. Recent advances prospects and problems in designing new strategies for oligonucleotide and gene delivery in therapy
22. Gene therapy: Promises, problems and prospects
23. Adeno-associated vires vectors for gene therapy
24. Adenoviral vectors for gene transfer
25. Viral vectors for gene therapy
26. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector
27. Adenoviral/retroviral vector chimeras: A novel strategy to achieve high efficiency transduction in vivo
28. Association of angiotensin II type I receptor polymorphism with resistant essential hypertension
29. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition
30. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type I receptor antisense
31. Losartan versus gene therapy: Chronic control of high blood pressure in spontaneously hypertensive rats
32. 1 receptor antisense
33. 1 receptor antisense gene therapy in hypertensive rat offspring
34. Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA
35. The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease
36. Current perspectives on the use of gene therapy for hypertension
37. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
38. Molecular and cellular mechanisms regulating vascular function and structure: Implications in the pathogenesis of hypertension
39. New contributions to clinical hypertension from molecular biology
40. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension
41. Antisense inhibition of hypertension in the spontaneously hypertensive rat
42. 1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin
43. Somatic gene therapy for hypertension
44. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats
45. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats
46. Efficacy and safety analyses of a recombinant human immunodeficiency virus vector system
47. Self-inactivating lentiviral vectors with U3 and U5 modifications
48. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
49. Ligand inducible and liver specific target gene expression in transgenic mice
50. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
51. A humanized system for pharmacologic control of gene expression